Page 3 - Pharma

1 drug sample spurious and nearly 48 substandard in June inspection

Eye-drops made by Indiana Ophthalmics in Gujarat that have been under the scanner also feature in the list

Explained: Toxic cough syrups and India's pharma oversight

Top Headlines: Lapses in pharma regulation, IPL's valuation rises 80%

Business Standard brings you the top headlines at this hour

Neuro feedback devices that read your mind are here

Mind-reading devices read the movement of pupils, heart rates and brain impulses. They will be able to predict human movement, action and thought

AstraZeneca announces launch of cancer medication Tremelimumab in UAE

AstraZeneca has announced the launch of its revolutionary cancer medication, IMJUDO (tremelimumab) in the UAE

Looking for opportunities in China after registering legal entity: Moderna

The U.S. biotech firm registered a unit called Moderna (China) Biotech Ltd in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers

Govt plans PLI for chemicals used in pharma, other industries: Mandaviya

Chemicals and Fertilisers Minister Mansukh Mandaviya on Friday asked pharma-medical devices industry to focus on manufacturing quality products at an affordable rates to compete globally, and announced plans to bring Product Linked Incentive (PLI) scheme for basic chemicals. Addressing an international conference on pharma and medical devices sector, the minister asserted that the Modi government is "pro-poor, pro-farmers but also industry-friendly" and said all policies are being framed after extensive consultations with the industry and other stakeholders. Mandaviya highlighted that India is the "pharmacy of the world" and the industry needs to focus on research and innovations, besides being aware of development across the world, to maintain its leadership position. He said the industry should be ready to face global competition. To win global competition, Mandaviya said there is a need to "bring affordability, and do quality manufacturing." "We have to advance our reputation w

Ayush, Minority Affairs ministries collaborate to promote Unani medicine

The ministries of Ayush and Minority Affairs have jointly taken a significant step to promote and develop the Unani system of medicine in India. The Ministry of Minorities Affairs has approved a grant of Rs 45.34 crore under the Pradhan Mantri Jan Vikas Karyakram (PMJVK), a centrally sponsored scheme (CSS), an Ayush Ministry statement said. With support of this scheme, Unani medicine facilities will be upgraded in Hyderabad, Chennai, Lucknow, Silchar and Bengaluru. The grant has been approved for establishing various facilities of Unani Medicine at these locations. The Central Council for Research in Unani Medicine (CCRUM) has been sanctioned a total of Rs 35.52 crore and the National Institute of Unani Medicine (NIUM), Bengaluru has been sanctioned Rs 9.81 crore, the statement said. A centre for fundamental research in Unani Medicine at National Research Institute of Unani Medicine for Skin Disorders, Hyderabad will be established at a cost of Rs 16.05 crore, it stated. The minis

India has developed its own mechanism for estimating TB burden: Mansukh

Union Minister of Health and Family Welfare, Mansukh Mandaviya, on Thursday said that India is the only country in the world to have developed its own mechanism for estimating its TB burden

Indian pharma firm Granules opens packaging facility in US' Virginia

Indian pharmaceutical company Granules has opened a packaging facility in the Virginia State of the US to expand the packaging capacity of essential drugs in the state, thus strengthening the biopharma supply chain. The facility was inaugurated by India's Ambassador to the US Taranjit Singh Sandhu. Granules, which was one of the first Indian pharmaceutical companies that received FDA authorization to export to the United States, has invested more than USD 100 million in the country, said Dr Krishna Prasad Chigurupati, the founder, chairman and managing director of the firm. "We have nearly 200 employees in Virginia with a large majority of them first-generation Indians," he said, adding the company also has a team of 30 scientists for research and development. Granules India Ltd produces some of the most widely used drugs, including Paracetamol, that have been very useful to billions across the world, Chigurupati said. "Happy to see Made in India' medicines value added in the US b

Abating pricing pressure in US market good news for pharma funds

While the risk from USFDA strictures remains, aggressive investors may take limited bets with 5-7-year horizon

Dr Reddy's acquires Mayne Pharma's USA prescription portfolio for $105 mn

The acquisition will complement DRL's US retail prescription pharmaceutical business with limited competition products

Pfizer enters talks to buy Seagen for over $30 billion, says report

Deal will help the firm add to its line-up of cancer treatments

With focus on non-US geographies, Amneal Pharma eyes India market

The company is actively recruiting its field force, and aims to have 600-700 medical representatives by the end of 2023

Centre plans to roll out research-linked incentive scheme for pharma sector

In the Union Budget 2023-24, Finance Minister Nirmala Sitharaman had hinted at fostering a research-driven climate in the pharma sector in India

Chennai-based firm's eye drops contaminated, says US FDA report

The US FDA said that using contaminated artificial tears increases risk of eye infections that could result in blindness or death

Enzene Biosciences raises $50 million, aims to expand into global markets

Enzene said it has built a highly experienced 400-person team under the leadership of Dr. Himanshu Gadgil, CEO at Enzene Biosciences Ltd

How a drug company made $114 billion by gaming the US patent system

The incident has become a case study in how drug companies artificially prop up prices of their best-selling drugs

Breather for Natco in Novartis cardiac drug case from Delhi High Court

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week

Uzbekistan cough syrup case: Production licence of Marion Biotech suspended

The production licence of Noida-based pharmaceutical firm Marion Biotech, allegedly linked with the deaths of children in Uzbekistan, has been suspended while the results of its controversial cough syrup are awaited, an Uttar Pradesh drug official said Thursday. A team of central agencies and the Uttar Pradesh drug department had carried out an inspection at the firm's office here on December 29 and taken six more samples for testing. During the inspection, the company representatives could not produce documents related to the production of 'Dok-1 max' cough syrup, prompting the government to order halting of its production immediately, Gautam Buddh Nagar Drug Inspector Vaibhav Babbar said. "The production licence of the firm remains suspended, as was ordered on December 29. Now the suspension order has been issued in writing to the firm on January 10 and has been acknowledged by the firm," Babbar told PTI. On the status of the test results, the officer said the samples were taken